Joanna Bartkowiak

Cardiologist at Bern University Hospital 🇨🇭

[Joanna Bartkowiak @joan_bartc]

50 day free access :
https://t.co/bU1UjCEXo6
Conventional echo parameters fail to adequately capture intrinsic RV function. Novel AI-derived metrics may improve TTVI risk stratification and help guide TTVI strategy (repair vs #TTVR)
@hahn_rt @FabienPraz @kovatti87
#treatTR

[RTHahnMD @hahn_rt]

Just published https://t.co/DOdgrMT5hF Hoping to standardize identification of appropriate patients for TTVI! @ESCardioNews @ESC_Journals @escardio @ACCinTouch @juliendreyfus1 @FabienPraz @NAjmoneMarsan @denisamuraru

[Thomas Pilgrim @ThomPilgrim]

In this RCT in TAVI patients, treatment with colchicine was associated with a lower risk of new-onset rhythm disturbances and subclinical leaflet thrombosis compared with placebo. The inflammatory response to TAVI may represent a novel therapeutic target. https://t.co/rCqbpCTgfN

[Thomas Pilgrim @ThomPilgrim]

Bicuspid anatomy can pose a significant challenge for TAVI: the combination of a substantial AVC calcium burden and a prominent raphe may define a particularly high risk phenotype. #JACCImaging https://t.co/aLxFXb7x44

[Daryoush Samim @DaryoushSamim]

❗Not all #bicuspid aortic valves (BAVs) behave similarly after #TAVI
⚠️ New high-risk phenotype identified: heavy cusp calcification + large raphe = >4× more periprocedural complications. @JACCJournals @ACCinTouch
check-out 👇
https://t.co/YbYhJZGCh0

[Daryoush Samim @DaryoushSamim]

In our 10-year prospective study of PMR patients undergoing M-TEER, MV anatomical characteristics significantly influenced symptomatic improvement & 1-year all-cause mortality. These features should be carefully considered for patient selection. Checkout👇🏽
https://t.co/9Vk1jhQaSM

[RTHahnMD @hahn_rt]

Two of our @Columbia @HeartValveCntr studies led by Robin LeRUZ made the impactful #tricuspid regurgitation papers list by PCR!! Great overview by @PCRonline! @JACCJournals @ACCinTouch @escardio @Europace

[RTHahnMD @hahn_rt]

@JACCJournals BEST OF JACC: CVImg 2006 https://t.co/0iLlRG1dAx. Our TR review TR made it!!! https://t.co/my4ZyscHiS @lpbadano @denisamuraru @FabienPraz @NAjmoneMarsan @joan_bartc @VDelgadoGarcia @juliendreyfus1 @j_hausleiter @PhilippLurz @drmaisano @JoaoLCavalcante @ACCinTouch @escardio

[Joanna Bartkowiak @joan_bartc]

@hahn_rt @Columbia @HeartValveCntr @PCRonline @JACCJournals @ACCinTouch @escardio @Europace Congratulations to you both! Well deserved!

[Thomas Pilgrim @ThomPilgrim]

In a post hoc analysis of the SCOPE trial, patients with obstructive CAD who underwent TAVR had comparable survival, patient-reported health status, and VARC-3 clinical efficacy compared with patients without CAD through 3 years of follow-up. https://t.co/RF8PDs61bX

[Thomas Pilgrim @ThomPilgrim]

The extent of cardiac damage significantly affects 10-year survival of patients with moderate and severe aortic stenosis. Cardiac damage staging might be as important as aortic stenosis grading in defining the prognosis of patients with aortic stenosis.
https://t.co/BMu2HmsuLI

[Alessandro Sticchi @Sticchi_Alex]

#CT #imaging suggests similar #eligibility x #TTVI & comparable TV anatomical phenotypes across severe, massive, and torrential #TR !

A pleasure to co-first author wth @DomAngellotti P. Kampaktsis, led by @OKhaliqueMD & @FabienPraz @joan_bartc @hahn_rt 🙏
@SpringerNature

[PCRonline 🫀 @PCRonline]

What’s new in the 2025 guidance on valvular heart disease?

📺https://t.co/zukV2M2KXU

@Sticchi_Alex interviews 🎤 @FabienPraz and Michael Borger, co-chairs of the 2025 ESC/EACTS Valvular Guidelines Task Force.

They discuss the major updates, including the central role of multimodality imaging, the lowered age threshold for TAVI, the distinction between atrial and ventricular secondary MR, evolving indications for tricuspid interventions, simplified antithrombotic strategies, and the importance of high-volume Heart Valve Centres.

[Domenico Angellotti @DomAngellotti]

TRISCEND II subanalysis showed greater benefit of TTVR in massive/torrential TR, suggesting this may be the target population (https://t.co/OLkOdJCnH4). In our paper just published, massive/torrential TR did not reduce TTVI eligibility vs severe TR (https://t.co/s8wVRaNOH3)

[Andrea Ruberti @a_rubi_5]

Sex-specific outcomes of T-TEER from the #TRISPA registry aligned with 2025 European Guidelines emphasizing sex-based valve treatment💥

Amazing mentorship of @freixa_xavier and support of @pedro_cepas

https://t.co/rDAwHCXHBJ

@RodrigoEstvez1 @FabienPraz @ESC_Journals #TreatTR

[Cardiovascular News @CN_publishing]

Live from #ESC2025: @piccoloraf presents results of PARTHENOPE - showing that a personalised post-PCI DAPT strategy was superior to a standard 12m approach, mainly driven by lower rate of ischaemic events, albeit with no major difference in bleeding events with the two strategies

[Joanna Bartkowiak @joan_bartc]

Great lecture by Prof. Gupta @aakriti_15 highlighting a more nuanced approach to timing intervention in patients with asymptomatic severe aortic valve stenosis — a new ! Class IIa indication for intervention in #VHD #guidelines

#ESCCongress
#esc2025
#ESC

[Joanna Bartkowiak @joan_bartc]

Congratulations to @hahn_rt on an outstanding lecture on the role of interventional imaging in transcatheter structural interventions, and on the well-deserved Award in Clinical Cardiology!
#ESCCongress #esc #esc2025

[Rodrigo Estévez @RodrigoEstvez1]

This is heritage
@FabienPraz

[Joanna Bartkowiak @joan_bartc]

Main takeaways from new #esc25 #VHD #guidelines:

Tricuspid and multivalvular VHD:

-> TV surgery if LHD surgery required + >= mod TR or dilated TV annulus

-> TTVI in high risk symptomatic severe TR

-> Treat symptomatic moderate AS&AR

-> Treat moderate AS&MR if EF <50%